MX387359B - Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos. - Google Patents

Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.

Info

Publication number
MX387359B
MX387359B MX2019010642A MX2019010642A MX387359B MX 387359 B MX387359 B MX 387359B MX 2019010642 A MX2019010642 A MX 2019010642A MX 2019010642 A MX2019010642 A MX 2019010642A MX 387359 B MX387359 B MX 387359B
Authority
MX
Mexico
Prior art keywords
intermediaries
mitogen
inhibitors
synthesis
activated kinase
Prior art date
Application number
MX2019010642A
Other languages
English (en)
Other versions
MX2019010642A (es
Inventor
Alexander L Ruchelman
Chengmin Zhang
Gregg Brian Feigelson
Hon- Wah Man
John F Traverse
Kelvin Hin- Yeong Yong
Maryll E Geherty
Mohit Kothare
Jr Richard Martin Heid
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2019010642A publication Critical patent/MX2019010642A/es
Publication of MX387359B publication Critical patent/MX387359B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a métodos para preparar un inhibidor de MK2, e intermediarios relacionados a los mismos.
MX2019010642A 2017-03-16 2018-03-15 Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos. MX387359B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472024P 2017-03-16 2017-03-16
PCT/US2018/022547 WO2018170203A1 (en) 2017-03-16 2018-03-15 Mk2 inhibitors, synthesis thereof, and intermediates thereto

Publications (2)

Publication Number Publication Date
MX2019010642A MX2019010642A (es) 2019-10-17
MX387359B true MX387359B (es) 2025-03-18

Family

ID=63523971

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010642A MX387359B (es) 2017-03-16 2018-03-15 Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.

Country Status (8)

Country Link
US (2) US10894796B2 (es)
EP (1) EP3596086A4 (es)
JP (1) JP7282039B2 (es)
CN (1) CN110678471B (es)
AU (1) AU2018236290B2 (es)
CA (1) CA3054826A1 (es)
MX (1) MX387359B (es)
WO (1) WO2018170203A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017005266B1 (pt) 2014-09-17 2022-11-01 Celgene Car Llc Compostos inibidores de mk2 e composição farmaceuticamente aceitável que os compreende
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
MX387359B (es) 2017-03-16 2025-03-18 Bristol Myers Squibb Co Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
WO2018170199A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Forms and compositions of a mk2 inhibitor
US11098057B2 (en) * 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2018170201A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
CN116670142A (zh) * 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
KR20240134978A (ko) 2022-01-14 2024-09-10 상하이 한서 바이오메디컬 컴퍼니 리미티드 피리딘 함유 폴리시클릭 유도체, 이의 제조 방법 및 용도
CN116643046B (zh) * 2023-05-30 2025-09-12 南昌市高新区人民医院(南昌大学第一附属医院高新医院) Mk2在癌症恶病质肌肉萎缩中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1747949A (zh) 2002-12-20 2006-03-15 法马西亚公司 无环吡唑化合物
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
JP2010505961A (ja) 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
CA2693904A1 (en) 2007-07-16 2009-01-22 Novartis Ag Heterocyclic compounds useful as mk2 inhibitors
EP2285800B1 (en) 2008-04-22 2011-11-16 Janssen Pharmaceutica, N.V. Quinoline or isoquinoline substituted p2x7 antagonists
CA2780333C (en) 2009-11-17 2016-05-24 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2012003498A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
PL2632925T3 (pl) 2010-10-29 2015-10-30 Pfizer N1/N2-laktamowe inhibitory karboksylazy acetylo-CoA
EP2635284B1 (en) * 2010-11-01 2019-12-18 Celgene CAR LLC Heterocyclic compounds and uses thereof
CA2819889C (en) * 2010-12-06 2020-12-15 Confluence Life Sciences, Inc. Substituted pyridinone-pyridinyl compounds
CA2878621C (en) 2012-07-10 2020-09-15 Ares Trading S.A. Pyrimidine pyrazolyl derivatives
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
CN104177340A (zh) * 2013-05-22 2014-12-03 中国中化股份有限公司 一种新型的喹唑啉（硫）酮类化合物及其用途
US10266654B2 (en) 2014-02-27 2019-04-23 Council Of Scientific & Industrial Research Poly-benzimidazole with pyrene and anthracene flourophore
EP3179858B1 (en) * 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
BR112017005266B1 (pt) * 2014-09-17 2022-11-01 Celgene Car Llc Compostos inibidores de mk2 e composição farmaceuticamente aceitável que os compreende
US10407422B2 (en) 2015-09-03 2019-09-10 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
MX387359B (es) 2017-03-16 2025-03-18 Bristol Myers Squibb Co Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
WO2018170201A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
WO2018170199A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Forms and compositions of a mk2 inhibitor
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
WO2022020562A1 (en) 2020-07-24 2022-01-27 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
CN116670142A (zh) 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体

Also Published As

Publication number Publication date
US20210139501A1 (en) 2021-05-13
US10894796B2 (en) 2021-01-19
WO2018170203A1 (en) 2018-09-20
CN110678471A (zh) 2020-01-10
JP7282039B2 (ja) 2023-05-26
CA3054826A1 (en) 2018-09-20
JP2020510063A (ja) 2020-04-02
MX2019010642A (es) 2019-10-17
US20200102326A1 (en) 2020-04-02
EP3596086A4 (en) 2020-12-16
AU2018236290B2 (en) 2022-06-02
AU2018236290A1 (en) 2019-09-19
CN110678471B (zh) 2022-09-13
EP3596086A1 (en) 2020-01-22
US11655257B2 (en) 2023-05-23

Similar Documents

Publication Publication Date Title
MX387359B (es) Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
CY1120988T1 (el) Παρεμποδιστες διαρυλ κινασης
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
IL282468A (en) 2- amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
CY1124097T1 (el) Κρυσταλλικο πολυμορφο της ελευθερης βασης της 2-υδροξυ-6-((2-(1-ισοπροπυλο-1η-πυραζολ-5-υλο)πυριδιν-3-υλο)μεθοξυ)βενζαλδεϋδης
MX373341B (es) INHIBIDORES DE PROTEíNA CINASA 2 ACTIVADA POR PROTEíNA CINASA ACTIVADA POR MITóGENO (MK2) Y SUS USOS.
MA51616A (fr) Inhibiteurs d'adn-pk
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
CY1125201T1 (el) Προφαρμακα του αναστολεα ειδικου προστατικου αντιγονου μεμβρανης (psma)
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
EA201891626A1 (ru) Ингибиторы тирозинкиназы брутона
AR111304A1 (es) Métodos para sintetizar un inhibidor de mcl-1
ECSP16067303A (es) Heteroarilos y usos de estos
AR095039A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
MX2017003930A (es) Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
EP3613737A4 (en) NEW CYCLINE-DEPENDENT KINASE CDK9 INHIBITOR
MX393600B (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
EA201992147A1 (ru) Ингибиторы тирозинкиназы брутона
ZA202002951B (en) Albumin-binding prodrugs of auristatin e derivatives
MX374654B (es) Compuestos útiles para inhibir ror-gamma-t.
CY1123406T1 (el) Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας
JOP20210036A1 (ar) مثبطات او- جليكوبروتين-2-أسيتاميدو-2-ديوكسي-3-دي-جلوكوبيرانوسيداز
HUE062726T2 (hu) 1-(1,2-dimetilpropil)-N-etil-5-metil-N-piridazin-4-il-pirazol-4-karboxamid kristályos formái
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.